Booz Allen Hamilton, in collaboration with Mindbreeze, is looking to deliver enterprise search capabilities for the Center for Drug Evaluation and Research (CDER) for the Food and Drug Administration (FDA), the company announced on Thursday.
Most recently, the FDA gave Booz Allen a contract to work with CDER in Feb. 2018 on a potential seven-year, $300 million blanket purchase agreement (BPA) to support its implementation of a transformational Informatics Platform.
"Our team of technologists and enterprise search experts are committed to transform FDA’s human drug review process leveraging enabling technologies that ultimately help bring live-saving treatments to market with greater speed and efficiency," added Dr. Roman Salasznyk, vice president at Booz Allen.
With Booz Allen’s partnership, Mindbreeze will support FDA staff by compiling more than 150 million submission documents, reviews and communications into a single user interface, making them available in a consolidated fashion. This involves machine learning and artificial intelligence (AI) supported search functions, as well as natural language processing.
“Our partner Booz Allen Hamilton has built up a wealth of expertise about Mindbreeze in recent years. Their implementation skills and commitment make them the perfect partner for us and our efforts to accelerate future large-scale projects across the US government and life sciences sectors,” said Daniel Fallmann, founder and CEO of Mindbreeze.
About Booz Allen Hamilton
For more than 100 years, military, government, and business leaders have turned to Booz Allen Hamilton to solve their most complex problems. As a consulting firm with experts in analytics, digital, engineering, and cyber, we help organizations transform.
We are a key partner on some of the most innovative programs for governments worldwide and trusted by their most sensitive agencies. We work shoulder to shoulder with clients, using a mission-first approach to choose the right strategy and technology to help them realize their vision.
